Tanshinone IIA arrests cell cycle and induces apoptosis in 786-O human renal cell carcinoma cells

Wei,Xianli; Zhou,Lunbin; Hu,Liangyong; Huang,Yaoxiong

doi:10.3892/ol.2012.626

Tanshinone IIA arrests cell cycle and induces apoptosis in 786-O human renal cell carcinoma cells

Authors:
- Xianli Wei
- Lunbin Zhou
- Liangyong Hu
- Yaoxiong Huang
View Affiliations

Affiliations: Department of Biomedical Engineering, Jinan University, Guangzhou, Guangdong 510632, P.R. China, Guangzhou Institute of Measuring and Testing Technology, Guangzhou, Guangdong 510030, P.R. China
Published online on: February 29, 2012 https://doi.org/10.3892/ol.2012.626
Pages: 1144-1148

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tanshinone IIA (Tan IIA), isolated from the Chinese medicinal herb Danshen, has been reported to have anticancer effects in several tumor models, while its effects on renal cell carcinoma have not been studied. In the present study, we evaluated the effects of Tan IIA on growth inhibition and apoptosis in the renal cancer cell line 786-O and its mechanism of action. Results of the MTT assay indicated that the treatment of 786-O cells with Tan IIA resulted in a concentration-dependent decrease in cell viability. Flow cytometry analysis revealed that Tan IIA treatment caused apoptosis following cell cycle perturbation. Furthermore, we examined the expression of cell cycle and apoptosis-related proteins using immunoblotting, which indicated an upregulation of p53, p21, bax and caspase-3 in Tan IIA-treated cells compared with Tan IIA-untreated cells. These results suggest that the activation of p53 and the upregulation of its target genes, including p21 and bax, may be involved in the mitochondrial apoptosis induced by Tan IIA in 786-O cells.

View Figures

View References

1	Bird J and Hayter M: A review of the literature on the impact of renal cancer therapy on quality of life. J Clin Nurs. 18:2783–2800. 2009. View Article : Google Scholar : PubMed/NCBI
2	Kyprianou N, Martikainen P, Davis L, English HF and Isaacs JT: Programmed cell death as a new target for prostatic cancer therapy. Cancer Surv. 11:265–277. 1991.PubMed/NCBI
3	Kyprianou N, Bains AK and Jacobs SC: Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate. 25:66–75. 1994. View Article : Google Scholar : PubMed/NCBI
4	Jang SI, Kim HJ, Kim YJ, Jeong SI and You YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol. 542:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
5	Li W, Li J, Ashok M, et al: A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol. 178:3856–3864. 2007. View Article : Google Scholar : PubMed/NCBI
6	Lin R, Wang WR, Liu JT, Yang GD and Han CJ: Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. J Ethnopharmacol. 108:217–222. 2006. View Article : Google Scholar : PubMed/NCBI
7	Wang AM, Sha SH, Lesniak W and Schacht J: Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother. 47:1836–1841. 2003.
8	Wang X, Wei Y, Yuan S, et al: Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer. 116:799–807. 2005. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Wang X, Jiang S, et al: Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol. 82:11–21. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
11	Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol. 17:4877–4882. 1997.PubMed/NCBI
12	el-Deiry WS: Regulation of p53 downstream genes. Semin Cancer Biol. 8:345–357. 1998. View Article : Google Scholar
13	Sun J, Tan BK, Huang SH, Whiteman M and Zhu YZ: Effects of natural products on ischemic heart diseases and cardiovascular system. Acta Pharmacol Sin. 23:1142–1151. 2002.PubMed/NCBI
14	Lu Q, Zhang P, Zhang X and Chen J: Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. Int J Mol Med. 24:773–780. 2009.PubMed/NCBI
15	Cao EH, Liu XQ, Wang JJ and Xu NF: Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radic Biol Med. 20:801–806. 1996. View Article : Google Scholar : PubMed/NCBI
16	Yu C, Friday BB, Lai JP, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 5:2378–2387. 2006. View Article : Google Scholar
17	Müller M, Wilder S, Bannasch D, et al: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 188:2033–2045. 1998.PubMed/NCBI